Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 149

Similar articles for PubMed (Select 9452285)

1.

Post-marketing surveillance of prophylactic mefloquine (Lariam) use in pregnancy.

Vanhauwere B, Maradit H, Kerr L.

Am J Trop Med Hyg. 1998 Jan;58(1):17-21.

2.

The effects of mefloquine treatment in pregnancy.

Nosten F, Vincenti M, Simpson J, Yei P, Thwai KL, de Vries A, Chongsuphajaisiddhi T, White NJ.

Clin Infect Dis. 1999 Apr;28(4):808-15.

3.

Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy.

Schlagenhauf P, Blumentals WA, Suter P, Regep L, Vital-Durand G, Schaerer MT, Boutros MS, Rhein HG, Adamcova M.

Clin Infect Dis. 2012 Jun;54(11):e124-31. doi: 10.1093/cid/cis215. Epub 2012 Apr 10.

4.

Safety of mefloquine and other antimalarial agents in the first trimester of pregnancy.

Phillips-Howard PA, Steffen R, Kerr L, Vanhauwere B, Schildknecht J, Fuchs E, Edwards R.

J Travel Med. 1998 Sep;5(3):121-6.

PMID:
9772329
5.

[Neuropsychiatric side effects of malarial prophylaxis with mefloquine (Lariam)].

Minei-Rachmilewitz T.

Harefuah. 1999 Jul;137(1-2):25-7, 87. Hebrew.

PMID:
10959270
6.

Pregnancy and mefloquine prevention of malaria.

[No authors listed]

Prescrire Int. 2000 Dec;9(50):180-1.

PMID:
11475498
7.

Mefloquine and malaria prophylaxis.

[No authors listed]

Drug Ther Bull. 1998 Mar;36(3):20-2. Review.

PMID:
9684417
8.

Mefloquine for malaria chemoprophylaxis 1992-1998: a review.

Schlagenhauf P.

J Travel Med. 1999 Jun;6(2):122-33. Review.

PMID:
10381965
9.

Limitations of postmarketing surveillance in the analysis of risk of pregnancy loss associated with maternal mefloquine exposure.

Nevin RL.

Clin Infect Dis. 2012 Oct;55(8):1167-8; author reply 1168-9. Epub 2012 Jul 3. No abstract available.

11.

The effects of inadvertent exposure of mefloquine chemoprophylaxis on pregnancy outcomes and infants of US Army servicewomen.

Smoak BL, Writer JV, Keep LW, Cowan J, Chantelois JL.

J Infect Dis. 1997 Sep;176(3):831-3.

12.

[Malaria chemoprophylaxis].

Petersen JE.

Ugeskr Laeger. 2005 Oct 17;167(42):3984-7. Review. Danish.

PMID:
16232397
13.

Mefloquine in the treatment of falciparum malaria during pregnancy in Eastern Sudan.

Adam I, Ali DA, Alwaseila A, Kheir MM, Elbashir MI.

Saudi Med J. 2004 Oct;25(10):1400-2.

PMID:
15494810
14.

Tolnaftate spray treatment during pregnancy.

Czeizel AE, Kazy Z, Puhó E.

Reprod Toxicol. 2004 May;18(3):443-4.

PMID:
15082081
15.
16.

Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum.

McGready R, Cho T, Keo NK, Thwai KL, Villegas L, Looareesuwan S, White NJ, Nosten F.

Clin Infect Dis. 2001 Dec 15;33(12):2009-16. Epub 2001 Nov 9.

18.

Serious adverse events of mefloquine in relation to blood level and gender.

Schwartz E, Potasman I, Rotenberg M, Almog S, Sadetzki S.

Am J Trop Med Hyg. 2001 Sep;65(3):189-92.

19.

[Spectacular suicide associated with mefloquine].

Jousset N, Guilleux M, de Gentile L, Le Bouil A, Turcant A, Rougé-Maillart C.

Presse Med. 2006 May;35(5 Pt 1):789-92. French.

PMID:
16710147
20.

Postmarketing surveillance for human teratogenicity: a model approach.

Chambers CD, Braddock SR, Briggs GG, Einarson A, Johnson YR, Miller RK, Polifka JE, Robinson LK, Stepanuk K, Lyons Jones K.

Teratology. 2001 Nov;64(5):252-61.

PMID:
11745831
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk